The use of low molecular weight heparin (LMWH) involves a diverse group of health professionals and patients. There is an education requirement to support the safe use of LMWHs and to promote best practice.
This document aims to ensure that all patients receive appropriate anticoagulation in a timely manner and to address prescribers’ concerns relating to the safe prescribing of LMWH. It is intended to promote consistent advice to patients via efficient and consistent clinical pathways for the prescribing and supply of LMWH.
|
This resource has been retired and is no longer considered an AWMSG-endorsed resource. The resource underwent an assessment for review in February 2025. At that time, members of the All Wales Prescribing Advisory Group (AWPAG) considered it appropriate to retire the resource. The content contained within the resource was considered to be out of date and other suitable alternative guidance was available (e.g. Parenteral anticoagulants (BNF) and NG89 Venous thromboembolism in over 16s (NICE)), AWPAG members considered it most appropriate for the resource to be retired at this time. If you think this resource should be reconsidered for review, please get in touch with AWTTC by emailing awttc@nhs.wales.uk. |
⇩ Prescribing of Low Moleculary Weight Heparin in Wales 1.4MB (PDF) |
(March 2010, Retired June 2025)